ArticleJACC. CardioOncology2023
Arterial Thromboembolism in Patients With AF and CHA
Article in JACC. CardioOncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Prevalence, Incidence, and Impact of Cancer in Atrial Fibrillation: A Systematic Review and Meta-Analysis of 70,000,000 Patients.Health science reports · 2026Review
- Contemporary management of atrial fibrillation in patients with cancer-the 2025 European Heart Rhythm Association survey.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Atrial fibrillation and ischemic stroke in cancer: the latest scientific evidence, current management, and future directions.Journal of thrombosis and thrombolysis · 2025Review
- CHAThe American journal of cardiology · 2025Article
- Atrial Fibrillation and Cancer: Pathophysiological Mechanism and Clinical Implications.Journal of clinical medicine · 2025Review
- Early Rhythm Control of Atrial Fibrillation in Cancer Survivors: A Nationwide Population-Based Study.Journal of the American Heart Association · 2025Observational
- Management of thrombocytopenia and anticoagulant therapy in patients with hematological malignancy on chemotherapy: a binational prospective study (TAT study).Journal of thrombosis and thrombolysis · 2025Article
- Incidence and risk of arterial thromboembolism in cancer patients from a safety-net healthcare system.Journal of thrombosis and haemostasis : JTH · 2025Article
- The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation: A Population-Based Cohort Study.JACC. CardioOncology · 2025Article
- Atrial Fibrillation and Cancer-Epidemiology, Mechanisms, and Management.Journal of clinical medicine · 2024Review
- Left Atrial Appendage Closure in Atrial Fibrillation Patients with Cancer.Journal of clinical medicine · 2024Article
- Arterial Thrombosis in Patients with Cancer.Cancers · 2024Review
- Epidemiology and Antithrombotic Therapy for Cancer-Associated Arterial Thromboembolism in Japan.JACC. CardioOncology · 2024Article
- Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact.JACC. CardioOncology · 2024Article
- Cancer and arterial thrombosis: therapeutic options.Research and practice in thrombosis and haemostasis · 2024Article
- Review
- To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy.JACC. CardioOncology · 2023Article
- Revisiting important issues in cancer and atrial fibrillation.Research and practice in thrombosis and haemostasis · 2023Article
- Systematic Review and Meta-Analysis of Oral Anticoagulant Therapy in Atrial Fibrillation Cancer Patients.Cancers · 2023Review
- CHAJACC. CardioOncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It is unclear whether newly diagnosed cancer adds to the risk of arterial thromboembolism (ATE) in patients with atrial fibrillation/flutter (AF). This is especially relevant for AF patients with low to intermediate CHA Objectives: The objectives were to evaluate the ATE risk in AF patients with a CHA Methods: A population-based retrospective cohort study was performed. Patients with a CHA Results: The 12-month cumulative incidence of ATE was 2.13% (95% CI: 1.47-2.99) in 1,411 AF patients with cancer and 0.8% (95% CI: 0.56-1.10) in 4,233 AF patients without cancer (HR: 2.70; 95% CI: 1.65-4.41). The risk was highest in men with CHA Conclusions: In AF patients with CHA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.